← SynDRA
TASIMELTEON
SynDRA canonical compound SYN0030027 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | MTNR1A | MTNR1B |
|---|
| Mechanism of action | melatonin receptor agonist |
|---|
| Indication | Non-24-Hour Sleep-Wake Disorder |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
- MTNR1A AGONIST
- Melatonin receptor agonist
- MTNR1B AGONIST
Drug classes
- Melatonin Receptor Agonists
- Melatonin Receptor Agonist
ATC classes
- N05C · HYPNOTICS AND SEDATIVES
Cross-references
Synonyms
- hetlioz
- VEC-162
- BMS-214778
- BMS-214,778
- Hetlioz
- Hetlioz lq
- VEC 162
- BMS 214778
- UNII-SHS4PU80D9
- SHS4PU80D9
- CHEBI:79042
- N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
- Tasimelteon [USAN:INN]
- tasimelteonum
- N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide
- N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
- N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide
- Hetlioz (TN)
- Tasimelteon (USAN/INN)
- SCHEMBL3505912
- GTPL7393
- HETLIOZ LQ
- BMS214778
- RefChem:57589
- DTXCID20132317
- N05CH03
- MFCD09033789
- Tasimelteon [USAN]
- Tasimelteon Impurity 1
- BMS-214778;VEC-162
- Tasimelteon (Standard)
- TASIMELTEON [MI]
- TASIMELTEON [INN]
- TASIMELTEON [VANDF]
- TASIMELTEON [MART.]
- TASIMELTEON [WHO-DD]
- orb1304147
- SCHEMBL29351713
Reported adverse events
- Alanine aminotransferase increased
- Headache
- Nightmare
- Upper respiratory tract infection
- Urinary tract infection
Look up TASIMELTEON in the interactive SynDRA portal →